Dyslipidemia, chronic inflammation, and subclinical atherosclerosis in children and adolescents infected with HIV: The PositHIVe Health Study

PLoS One. 2018 Jan 10;13(1):e0190785. doi: 10.1371/journal.pone.0190785. eCollection 2018.

Abstract

HIV-infected children and adolescents may be at risk for cardiovascular disease due to chronic inflammation and exacerbation of risk factors. The aim of this study was as follows: 1) compare cardiovascular risk factors, chronic inflammation, and carotid intima-media thickness (IMTc) between the HIV and control groups; 2) determine the association of HIV and antiretroviral (ART) regimens with cardiovascular risk factors, chronic inflammation, and IMTc; and 3) identify variables associated with elevated IMTc. Cross-sectional analysis of 130 children and adolescents, 8-15 years of age, divided into HIV-infected (n = 65) and healthy control (n = 65) participants. Body fat, blood pressure, glycemia, insulin, and glycated hemoglobin, total cholesterol and fractions (LDL-C and HDL-C), triglycerides, C-reactive protein (CRP), interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), and the IMTc were measured. The results showed HIV-infected children and adolescents had higher levels of glycemia (87.9 vs. 75.9 mg.dL-1, p< 0.001), LDL-c (94.7 vs. 79.5 mg.dL-1, p = 0.010), triglycerides (101.2 vs. 61.6 mg.dL-1, p< 0.001), CRP (1.6 vs. 1.0 mg.L-1, p = 0.007), IL-6 (1.42 vs. 0.01 pg.mL-1, p< 0.001), TNF-α (0.49 vs. 0.01 pg.mL-1, p< 0.001), mean IMTc (0.526 vs. 0.499 mm, p = 0.009), and lower HDL-c (53.7 vs. 69.4 mg.dL-1, p< 0.001) compared to controls. Systolic blood pressure (β = 0.006, p = 0.004) and TNF-α (β = -0.033, p = 0.029) accounted for 16% of IMTc variability in HIV-infected children and adolescents. In patients using protease inhibitors-based ART, male gender (β = -0.186, p = 0.008), trunk body fat (β = -0.011, p = 0.006), glucose (β = 0.005, p = 0.046), and IL-6 (β = 0.017, p = 0.039) accounted for 28% of IMTc variability. HIV-infected children and adolescents may be at risk for premature atherosclerosis due to chronic inflammation and dyslipidemia. Interventions with the potential to improve lipid profile, mitigate inflammation, and reduce cardiovascular risk are needed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiposity
  • Adolescent
  • Anti-Retroviral Agents / therapeutic use
  • Atherosclerosis / complications*
  • Atherosclerosis / diagnostic imaging
  • Atherosclerosis / epidemiology
  • Atherosclerosis / physiopathology
  • Biomarkers / blood
  • Blood Glucose
  • Carotid Intima-Media Thickness
  • Child
  • Cross-Sectional Studies
  • Dyslipidemias / complications*
  • Dyslipidemias / diagnostic imaging
  • Dyslipidemias / epidemiology
  • Dyslipidemias / physiopathology
  • Female
  • HIV Infections / complications*
  • HIV Infections / diagnostic imaging
  • HIV Infections / drug therapy
  • HIV Infections / physiopathology
  • Humans
  • Inflammation / complications*
  • Inflammation / diagnostic imaging
  • Inflammation / epidemiology
  • Inflammation / physiopathology
  • Interleukin-6 / blood
  • Lipids / blood
  • Male
  • Protease Inhibitors / therapeutic use
  • Risk Factors
  • Sex Factors

Substances

  • Anti-Retroviral Agents
  • Biomarkers
  • Blood Glucose
  • IL6 protein, human
  • Interleukin-6
  • Lipids
  • Protease Inhibitors

Grants and funding

This study was awarded a scholarship from the Coordination of Improvement of Higher Education Personal (CAPES). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.